ALTHEUS THERAPEUTICS

Altheus Therapeutics, Inc. is developing Zoenasa® Oral Tablets and Rectal Gel formulations as novel front-line therapies for the treatment of ulcerative colitis and other inflammatory bowel diseases (IBD). Current front-line therapy for ulcerative colitis is the anti-inflammatory mesalamine (5-aminosalicylic acid; 5-ASA). Zoenasa is a fixed-dose combination of mesalamine plus the powerful antioxidant and anti-inflammatory agent N-acetylcysteine to reduce mucosal injury associated with inflammat... ory bowel disease. Zoenasa will be available as Oral Tablets with an extended- and delayed-release profile for long term therapy in patients with proximal or extensive colitis; as a Rectal Gel for short term therapy in patients suffering from left-sided (distal) ulcerative colitis; and in other specialized formulations. In both animal and human research studies, the Zoenasa combination has demonstrated dramatic efficiacy benefits over mesalamine monotherapy. Altheus believes that Zoenasa will open an important new category in ulcerative colitis, mesalamine combination therapy.

#SimilarOrganizations #People #Website #More

ALTHEUS THERAPEUTICS

Industry:

Biotechnology Health Care Health Diagnostics

Founded:

2006-01-01

Address:

Oklahoma City, Oklahoma, United States

Country:

United States

Website Url:

http://www.altheustherapeutics.com

Total Employee:

Status:

Active

Contact:

(405) 319-8177

Email Addresses:

[email protected]

Total Funding:

10.06 M USD

Technology used in webpage:

Viewport Meta IPhone / Mobile Compatible Google Font API WordPress Font Awesome Domain Not Resolving Apache Wordpress Plugins Mobile Non Scaleable Content Sitelinks Search Box